In our study, we found that the SGLT2 inhibitor significantly inhibited osteosarcoma tumor growth in vivo, which could be attributed to the up-regulation of STING expression and activation of the IRF3/IFN-β pathway induced by the SGLT2 inhibitor. Here, IRF3 is linked to osteosarcoma.